Current treatment of Type 1 Diabetes (T1D) consists only of exogenous insulins and Symlin. But these existing agents fail to address the lack of sustained / intrinsic control of T1D and none address the autoimmune component of T1D’s etiology. Innovative approaches are based on immune modulation and cell-based therapies. In this digest, we have focused on BLA filing of first disease-modifying T1D therapy, automation in T1D management, T-cell based therapies